RA CAPITAL MANAGEMENT, L.P. purchased $413K of ARTV (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 41,319 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at $9.99 ($0.41M total) on 2026-07-24.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 28, 2026, 9:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 28, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARTV
Bullish
medium confidence
Mentioned
$ARTV
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARTVBullishLow
01

Why it matters

The newest fact is the reported open-market purchase size, price, and post-transaction indirect holdings, which may slightly influence sentiment but does not change fundamentals in the text.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without accompanying business updates.

03

What to watch

Indirect holdings and role-based reporting can obscure the true economic exposure and timing; traders should not treat this as a substitute for upcoming clinical or financial catalysts.

Relevance 5/10Novelty 5/10Timing: filed 2026-07-28 after-hours, covering a 2026-07-24 purchase

Background

The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc. (ARTV).

Company-level read

Ticker impact

$ARTVBullishMedium confidence
Context

RA Capital Management, L.P. reported an open-market purchase of 41,319 shares of Artiva Biotherapeutics at $9.9900 on 2026-07-24.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

This is a primary-source insider transaction disclosure with defined size and price, but it does not include new operating, clinical, or financial information that would re-rate the business.

Market effects

No direct sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider buys under a 10b5-1 plan are often more informative; here the filing states no pre-arranged 10b5-1 plan, which can also mean the trade may be opportunistic rather than thesis-driven.

Key entities

  • Artiva Biotherapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • RA Capital Management, L.P.

    Reported an open-market purchase as a director and 10% owner with indirect holdings.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Low

Artiva Ends AlloNK Autoimmune Cell Therapy After Two Trial Deaths, One Unexplained, and Cuts 94% of Staff

Artiva Biotherapeutics halted its AlloNK cell therapy trial for autoimmune diseases after two participant deaths, one linked to chemotherapy. The company will cut 94% of its staff and explore strategic options, including a sale or dissolution. AlloNK was tested with rituximab in rheumatoid arthritis and other autoimmune diseases. Artiva reported $319.1 million in cash as of September 30.

$ARTVMed

Jefferies downgrades Artiva Biotherapeutics stock rating to hold

Jefferies downgraded Artiva Biotherapeutics (ARTV) to Hold with a $4.00 price target after the company discontinued its AlloNK program due to safety concerns and lack of long-term efficacy in rheumatoid arthritis patients. The stock is down 31% over the past week. The company is cutting 94% of staff and exploring strategic alternatives, though it has strong short-term liquidity. Analysts have mixed views, with some maintaining bullish ratings and high price targets.

MedAI 8/10

Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Artiva Biotherapeutics is halting its lead cell therapy program, AlloNK, after two patient fatalities in a mid-stage trial and updated clinical data raising concerns about its efficacy. The company will lay off 94% of its staff and has $319.1 million in cash. Analysts note potential implications for Nkarta and Fate Therapeutics, with Nkarta's upcoming data presentation under scrutiny.